Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yttrium (90Y) rosopatamab
- Development stage
- Unknown
- Lead developer
- Convergent Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
90Y-J591 is a radioimmunotherapy agent comprising the deimmunized monoclonal antibody J591 (rosopatamab) labeled with the beta-emitting radioisotope Yttrium-90 (90Y). The antibody J591 specifically targets the extracellular domain of Prostate-Specific Membrane Antigen (PSMA), a protein highly overexpressed on the surface of prostate cancer cells and the neovasculature of various solid tumors. Upon binding to PSMA, the complex is internalized, and the high-energy beta particles emitted by 90Y cause lethal double-stranded DNA breaks in the target and neighboring cells via the crossfire effect. Developed primarily for metastatic castration-resistant prostate cancer (mCRPC), it has been studied in both single-dose and fractionated regimens to optimize the balance between anti-tumor efficacy and bone marrow toxicity.
- Other names
- Yttrium-90 J591Yttrium90 J591Yttrium 90 J59190Y-rosopatamab
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on yttrium (90Y) rosopatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yttrium (90Y) rosopatamab.